In COVID-19 clinical update #54, Daniel Griffin covers effectiveness of 3 vs 6 ft physical distancing, effectiveness of masks, physical distancing, and eye shields, second vaccine dose completion, alleviation of COVID-19 symptoms after vaccination, vaccine trials in children, and IDSA approval of a mAb cocktail.
Forest and Maria-Isabel join TWiV to discuss their their project to engage thousands of citizens to swab inanimate surfaces in the San Diego area, then send the samples to the Rohwer Lab for nucleic acid analysis.
On a TWiV tetramer, we review the ongoing outbreaks of Ebolavirus disease in DRC and Guinea, evidence that SARS-CoV-2 infections in children are far more prevalent than are being detected, and recent long COVID estimates from the UK.
In COVID-19 clinical update #53, Daniel Griffin reviews underreporting of infections and long term disease in children, a blood test for T cells, results of phase 3 trials for monoclonal antibodies, preliminary findings on an oral antiviral, clinical trial of ivermectin, and recommendations for upcoming gatherings.
Matt Frieman returns to TWiV to discuss the COVID-19 pandemic from the point of view of a coronavirologist, including his work with Novavax on their spike protein-based vaccine.
In COVID-19 clinical update #52, Daniel Griffin reviews differences in attack rates between children and adults, J&J vaccine phase III data, G6PD deficiency and vaccines, NIH halts convalescent plasma trial, dexamethasone in hospitalized patients, data on tocilizumab, and long COVID in children.
Ginger Campbell joins TWiV to discuss palliative care for COVID-19 patients, and how to approach the disease from a goals of care perspective.
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia, and increased Ct values after administration of mRNA vaccine.
Paul Offit joins TWiV to discuss all things vaccine, including how COVID-19 vaccine development was accelerated, whether the vaccines are safe and efficacious, the difference between an EUA and a licensed vaccine, sterilizing immunity, herd immunity, and much more.
TWiV explores single dose administration and timing of second dose of AZD1222 COVID-19 vaccine, safety and efficacy of Sputnik V, and control of coronavirus recombination by a viral proofreading exonuclease.
